Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.140
+0.310 (10.95%)
At close: Feb 27, 2026, 4:00 PM EST
3.120
-0.020 (-0.64%)
After-hours: Feb 27, 2026, 7:52 PM EST
Acumen Pharmaceuticals Employees
Acumen Pharmaceuticals had 61 employees as of December 31, 2024. The number of employees increased by 9 or 17.31% compared to the previous year.
Employees
61
Change (1Y)
9
Growth (1Y)
17.31%
Revenue / Employee
n/a
Profits / Employee
-$2,186,082
Market Cap
190.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 61 | 9 | 17.31% |
| Dec 31, 2023 | 52 | 12 | 30.00% |
| Dec 31, 2022 | 40 | 23 | 135.29% |
| Dec 31, 2021 | 17 | 10 | 142.86% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 279 |
| Sangamo Therapeutics | 183 |
| Fate Therapeutics | 181 |
| Innate Pharma | 174 |
| ProQR Therapeutics | 166 |
| Molecular Partners AG | 153 |
| Rani Therapeutics Holdings | 106 |
| Vaxart | 105 |
ABOS News
- 3 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 7 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 8 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 8 months ago - Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025 - GlobeNewsWire